{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:08Z","timestamp":1789387568860,"version":"build-2803163510"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy has improved outcomes for patients with esophageal squamous cell carcinoma (ESCC), yet a substantial proportion develop resistance. The tumor microenvironment (TME) drives this resistance through four hallmarks: physical barriers formed by cancer-associated fibroblast (CAF)-deposited extracellular matrix (ECM) and elevated interstitial fluid pressure (IFP), enrichment of immunosuppressive cells, effector T cell exhaustion, and impaired antigen presentation. Radiotherapy, a cornerstone of ESCC treatment, has the potential to simultaneously target these barriers through multiple complementary mechanisms. Preclinical evidence suggests that high-dose or ablative radiotherapy can drive CAFs into irreversible senescence, triggering a senescence-associated secretory phenotype (SASP) that upregulates matrix metalloproteinases (MMPs) and degrades ECM. In preclinical models, IFP can be reduced through vascular normalization (low-dose) or tumor debulking (high-dose). There is also evidence, largely from experimental systems, that radiotherapy may eliminate immunosuppressive cells, ameliorate T cell exhaustion, and upregulate MHC class I and PD-L1 expression to restore immune recognition. These immunomodulatory effects appear to be dose- and fractionation-dependent; conventional fractionation often falls below the threshold required to dismantle the physical barrier\u2014a factor that is hypothesized to contribute to, but does not fully account for, the limited success of chemo-immuno-radiotherapy trials to date. Building on this mechanistic framework, we evaluate clinical evidence for radiotherapy-immunotherapy combinations in ICI-resistant ESCC, compare the distinct roles of stereotactic body radiotherapy (SBRT) and low-dose radiotherapy (LDRT), and propose a \u201cbarrier-exhaustion score\u201d as a hypothetical tool to guide individualized treatment. This review provides a mechanistic rationale and clinical perspective for radiotherapy-based strategies to overcome immunotherapy resistance in ESCC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1905086","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:41:27Z","timestamp":1789386087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy for overcoming immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Changjiang","family":"Du","sequence":"first","affiliation":[{"name":"First Clinical Medical College of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology Digestive, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1906395","article-title":"Acquired resistance to first-line immune checkpoint inhibitors in esophageal squamous cell carcinoma: progression patterns and prognostic implications","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114328","article-title":"Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study","volume":"212","author":"Meng","year":"2024","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae245","article-title":"Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study","volume":"30","author":"Hong","year":"2024","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0530","article-title":"Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer","volume":"73","author":"Bochet","year":"2013","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013959","article-title":"An immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma","volume":"14","author":"Wan","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216108","article-title":"Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance","volume":"559","author":"Peng","year":"2023","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2217\/14796694.4.6.793","article-title":"Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis","volume":"4","author":"Lunt","year":"2008","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114301","article-title":"Modulating tumor physical microenvironment for fueling CAR-T cell therapy","volume":"185","author":"Luo","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1038\/s41467-021-25539-x","article-title":"Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10495-025-02256-0","article-title":"Progenitor CD8+ T cells and hyper-Treg crosstalk: a driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma","volume":"31","author":"Huang","year":"2026","journal-title":"Apoptosis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2407506121","article-title":"QSOX1 facilitates dormant esophageal cancer stem cells to evade immune elimination via PD-L1 upregulation and CD8 T cell exclusion","volume":"121","author":"Wei","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.06.003","article-title":"Cancer stem cell mimicry for immune evasion and therapeutic resistance","volume":"31","author":"Saw","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi4191","article-title":"A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression","volume":"9","author":"Plebanek","year":"2024","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado3032","article-title":"Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate","volume":"10","author":"Huang","year":"2025","journal-title":"Sci Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2025.01.001","article-title":"Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression","volume":"178","author":"Li","year":"2025","journal-title":"Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10565-025-10102-x","article-title":"CBX6 induces CD8+ T cell exhaustion and tumor development in esophageal squamous cell carcinoma through SMARCD1-mediated CCL8 secretion and lactate efflux","volume":"41","author":"Wang","year":"2025","journal-title":"Cell Biol Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.118269","article-title":"MIF-expressing tumor cells mediate immunotherapeutic resistance in esophageal squamous cell carcinoma","volume":"16","author":"Song","year":"2026","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604715","article-title":"Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma","volume":"99","author":"Mizukami","year":"2008","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020169","article-title":"Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8227-9","article-title":"T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract","volume":"50","author":"Lu","year":"2011","journal-title":"Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doag063","article-title":"CD39 and PD-L1 co-expression may serve as potential indicators for evaluating the efficacy of neoadjuvant immunotherapy in esophageal squamous cell carcinoma","volume":"39","author":"Wu","year":"2026","journal-title":"Dis Esophagus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008662","article-title":"CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs","volume":"12","author":"Xiong","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12964-025-02138-7","article-title":"Cancer-associated fibroblasts: a pivotal regulator of tumor microenvironment in the context of radiotherapy","volume":"23","author":"Zheng","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1132","article-title":"Human lung fibroblasts prematurely senescent after exposure to ionizing radiation enhance the growth of Malignant lung epithelial cells in vitro and in vivo","volume":"39","author":"Papadopoulou","year":"2011","journal-title":"Int J Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.matbio.2017.10.004","article-title":"Extracellular matrix alterations in senescent cells and their significance in tissue homeostasis","author":"Mavrogonatou","year":"2019","journal-title":"Matrix Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/aging.100989","article-title":"Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-\u03b2","volume":"8","author":"Liakou","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3892\/or.2024.8788","article-title":"Metformin suppresses esophageal cancer progression through the radiation-induced cellular senescence of cancer-associated fibroblasts","volume":"52","author":"Sugimoto","year":"2024","journal-title":"Oncol Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.152654","article-title":"Single-cell and spatial transcriptomics reveal SPRR2A+ epithelial-MMP1+ fibroblast interactions as key drivers of Esophageal Squamous Cell Carcinoma progression","author":"Yang","year":"2026","journal-title":"Int J Biol Macromol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b06301","article-title":"Radiation and heat improve the delivery and efficacy of nanotherapeutics by modulating intratumoral fluid dynamics","volume":"12","author":"Stapleton","year":"2018","journal-title":"ACS Nano"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/028418601750288262","article-title":"Radiobiological hypoxia, oxygen tension, interstitial fluid pressure and relative viable tumour area in two human squamous cell carcinomas in nude mice during fractionated radiotherapy","volume":"40","author":"Baumann","year":"2001","journal-title":"Acta Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-025-02477-4","article-title":"Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1\/2 trial (PALACE-2)","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10388-025-01165-0","article-title":"Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)","volume":"23","author":"Hong","year":"2025","journal-title":"Esophagus"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233890","article-title":"The interface of tumour-associated macrophages with dying cancer cells in immuno-oncology","volume":"11","author":"Vanmeerbeek","year":"2022","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00828","article-title":"Reprogramming of tumor-associated macrophages with anticancer therapies: Radiotherapy versus chemo- and immunotherapies","volume":"8","author":"Genard","year":"2017","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay9789","article-title":"Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming","volume":"6","author":"Wan","year":"2020","journal-title":"Sci Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1103149","article-title":"Tumor-associated macrophage polarization in the inflammatory tumor microenvironment","volume":"13","author":"Zou","year":"2023","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-025-13801-0","article-title":"Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma","volume":"25","author":"Yin","year":"2025","journal-title":"BMC Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12967-026-08004-5","article-title":"Dissecting the immunosuppressive microenvironment of LAMA3\u2009+\u2009malignant cells and SPP1\u2009+\u2009macrophages in esophageal squamous cell carcinoma using single-cell and spatial transcriptomics","volume":"24","author":"Hong","year":"2026","journal-title":"J Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: Shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1644645","article-title":"Exosomal FABP5 drives HCC progression via macrophage lipid metabolism and immune microenvironment remodeling","volume":"16","author":"Siyi Luo","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178337","article-title":"The generation, activation, and polarization of monocyte-derived macrophages in human Malignancies","volume":"14","author":"Chaintreuil","year":"2023","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944142","article-title":"The delivery of extracellular \u201cdanger\u201d signals to cytosolic sensors in phagocytes","volume":"13","author":"Gonzales","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"Luke","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Daniel S Chen","year":"2017","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2174721","article-title":"Stereotactic ablative radiation therapy in 3 fractions induces a favorable systemic immune cell profiling in prostate cancer patients","volume":"12","author":"Belinda Palermo","year":"2023","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189302","article-title":"Radiotherapy modulates autophagy to reshape the tumor immune microenvironment to enhance anti-tumor immunity in esophageal cancer","volume":"1880","author":"Suna Zhou","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119118","article-title":"Manipulation of tumor microenvironment by induction of immunogenic cell death and immune check point inhibitors for enhancing the efficacy of cancer treatments","volume":"196","author":"Abdullah Moridikia","year":"2026","journal-title":"BioMed Pharmacother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"M 27657168","DOI":"10.7554\/eLife.17979","article-title":"CD301b+ dendritic cells suppress T follicular helper cells and antibody responses to protein antigens","volume":"5","author":"Yosuke Kumamoto","year":"2016","journal-title":"Elife"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638873","article-title":"Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers","volume":"11","author":"Yuehong Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Laurel B Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271205","article-title":"Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma","volume":"17","author":"Shohei Katsuki","year":"2022","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","article-title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients","volume":"43","author":"Jianzhou Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339857","article-title":"TREX1 dictates the immune fate of irradiated cancer cells","volume":"6","author":"Claire Vanpouille-Box","year":"2017","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Claire Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"40577","DOI":"10.1038\/s41598-025-24396-8","article-title":"Radiation regulates the expression of HLA-I in esophageal squamous cell carcinoma through interferon-\u03b3","volume":"15","author":"Shanshan Shao","year":"2025","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0098","article-title":"Retinoic acid modulates interferon-\u03b3 production by hepatic natural killer T cells via phosphatase 2A and the extracellular signal-regulated kinase pathway","volume":"35","author":"Heng-Kwei Chang","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12026-019-09111-w","article-title":"Promotion on NLRC5 upregulating MHC-I expression by IFN-\u03b3 in MHC-I-deficient breast cancer cells","volume":"67","author":"Ming-Zhen Zhao","year":"2019","journal-title":"Immunol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120921","article-title":"STAT1-mediated down-regulation of Bcl-2 expression is involved in IFN-\u03b3\/TNF-\u03b1-induced apoptosis in NIT-1 cells","volume":"10","author":"Zhao-hui Cao","year":"2015","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Eric A Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Simon J Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509051","article-title":"Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy","volume":"15","author":"Lovis Hampe","year":"2024","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114188","article-title":"Maximizing survival benefit with precision therapy based on progressive patterns after immunochemotherapy in metastatic esophageal cancer","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109679","article-title":"Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial","volume":"184","author":"Wensi Zhao","year":"2023","journal-title":"Radiother Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12672-026-05149-z","article-title":"Comparing immunotherapy re-challenge plus chemoradiotherapy versus chemoradiotherapy alone in metastatic esophageal squamous cell carcinoma after first-line immunotherapy failure","volume":"17","author":"Song","year":"2026","journal-title":"Discover Oncol"},{"key":"B79","article-title":"A phase II, single-Arm, prospective study of cadonilimab (AK104) combined with radiotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma after progression on anti\u2013PD-(L)1 therapy","year":"2026"},{"key":"B80","article-title":"Low-Dose radiotherapy in patients with advanced esophageal squamous cell carcinoma resistant to first-Line chemotherapy combined with immunotherapy","year":"2025"},{"key":"B81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1667\/rr14951.1","article-title":"In vitro radiobiological advantages of hypofractionation compared with conventional fractionation: Early-passage NSCLC cells are less aggressive after hypofractionation","volume":"190","author":"Zhang","year":"2018","journal-title":"Radiat Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1905086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:41:28Z","timestamp":1789386088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1905086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2026.1905086"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1905086","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1905086"}}